Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459758 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL25909777 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL10183113 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL25915782 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10P2RX7 | |
| SCHEMBL22102661 | 0.70 | — | — | |
| SCHEMBL15113582 | 0.68 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25915799 | 0.68 | MAPK1 (0.43) | KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL25909778 | 0.67 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL10183041 | 0.66 | KDM4E (0.36) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL25913034 | 0.66 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | KDM4E 3968/4885ALDH1A1 1635/4885HPGD 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.